- Biomea Fusion Announces BMF-219 in Diabetes Placed on Clinical Hold
- Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
- Biomea Fusion Announces Completion of Enrollment of First 3 Arms in Phase 2 Expansion Cohorts of COVALENT-111 Study for BMF-219 in Type 2 Diabetes
- Biomea Fusion Reports First Quarter 2024 Financial Results and Corporate Highlights
- Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- Biomea Fusion Highlights Initial Data from the First Two Type 1 Diabetes Patients Dosed with BMF-219
- Biomea Fusion Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights
- Biomea Fusion Presents Patient Cohorts in COVALENT-111 Displaying a Durable Placebo-Adjusted Mean Reduction of up to 1.4% in HbA1c While Off Therapy at Week-26, after BMF-219’s 28-Day Treatment Cycle, Supporting Improved Pancreatic Function
- Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- Biomea Fusion Highlights Recent Updates and Anticipated 2024 Corporate Milestones at 42nd Annual J.P. Morgan Healthcare Conference
More ▼
Key statistics
On Tuesday, Biomea Fusion Inc (BMEA:NSQ) closed at 4.43, 22.71% above the 52 week low of 3.61 set on Jun 07, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 4.41 |
---|---|
High | 4.68 |
Low | 4.35 |
Bid | 4.43 |
Offer | 4.48 |
Previous close | 4.42 |
Average volume | 1.81m |
---|---|
Shares outstanding | 35.94m |
Free float | 26.91m |
P/E (TTM) | -- |
Market cap | 158.88m USD |
EPS (TTM) | -3.57 USD |
Data delayed at least 15 minutes, as of Jul 02 2024 21:00 BST.
More ▼